NASDAQ$LGVN
Longeveron Inc-A · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported third quarter financial results and provided a business update.
Longeveron Inc. reported financial results for the quarter ended September 30, 2024, and provided a business update, highlighting the advancement of Lomecel-BTM for HLHS and mild Alzheimer’s disease.
- Advanced Lomecel-BTM development for Hypoplastic Left Heart Syndrome (HLHS) and mild Alzheimer’s disease.
- Achieved over 80% enrollment in the ELPIS II clinical trial for HLHS.
- FDA confirmed ELPIS II is pivotal and acceptable for BLA submission for full traditional approval if positive.
- CLEAR MIND Phase 2a clinical data in mild Alzheimer’s disease selected for presentation at AAIC and CTAD24.
Headline financials
Revenue & EPS history
Longeveron · Revenue · Quarterly
$773K
Revenue by segment
Longeveron · $150K total across 1 segment · Q4 2023
- Clinical Trial Revenue$150K—100.0%
Forward guidance
Longeveron is focused on advancing its clinical programs and anticipates key milestones in the development of Lomecel-BTM for HLHS and Alzheimer's disease.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-5.1%
Avg return
Earnings day
-5.7%
Avg return
5 days after
+23.1%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+10.0%
Q1 2022
Best reaction
-35.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -11.0% | — | |
| Q4 2025 | -4.7% | -0.7% | +6.1% | |
| Q3 2025 | -4.3% | -7.3% | -23.1% | |
| Q1 2025 | -10.1% | -9.4% | -17.4% | |
| Q4 2024 | -9.2% | -5.3% | +2.0% | |
| Q3 2024 | -2.3% | -8.8% | -14.3% | |
| Q2 2024 | -7.5% | -11.3% | -21.8% | |
| Q1 2024 | +3.1% | -1.5% | +106.9% | |
| Q4 2023 | +0.7% | +0.0% | -39.8% | |
| Q3 2023 | -6.7% | -0.5% | +17.6% | |
| Q2 2023 | -6.5% | -12.0% | -25.8% | |
| Q1 2023 | -6.1% | -11.9% | -0.9% | |
| Q4 2022 | -15.5% | -17.5% | -25.0% | |
| Q3 2022 | +5.1% | +2.6% | -14.1% | |
| Q2 2022 | +3.9% | +1.3% | -14.5% | |
| Q1 2022 | +10.0% | +16.2% | -0.7% | |
| Q4 2021 | -14.4% | -7.1% | +37.8% | |
| Q3 2021 | -4.9% | -15.6% | +461.6% | |
| Q2 2021 | -35.7% | -32.9% | -31.1% | |
| Q1 2021 | +1.7% | +17.9% | +35.8% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro